Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS : results from the Big MS Data Network
Lorscheider, Johannes (University of Basel)
Signori, Alessio (University of Genoa (Itàlia))
Subramaniam, Suvitha (University Hospital Basel (Basilea, Suïssa))
Benkert, Pascal (University Hospital Basel (Basilea, Suïssa))
Vukusic, Sandra (Université de Lyon (França))
Trojano, Maria (Università degli Studi di Bari Aldo Moro)
Hillert, Jan (Karolinska Institute (Estocolm, Suècia))
Glaser, Anna (Karolinska Institute (Estocolm, Suècia))
Hyde, Robert
Spelman, Tim (Karolinska Institute (Estocolm, Suècia))
Magyari, Melinda (Copenhagen University Hospital Rigshospitalet (Dinamarca))
Elberling, Frederik (Rigshospitalet Glostrup (Dinamarca))
Pontieri, Luigi (Rigshospitalet Glostrup (Dinamarca))
Koch-Henriksen, Nils (Aarhus University Hospital (Aarhus, Dinamarca))
Sørensen, Per S. (Rigshospitalet Glostrup (Dinamarca))
Gerlach, Oliver (Maastricht University Medical Center)
Prat, Alexander (Hôpital Notre Dame, CHUM and Universite de Montreal(Canadà))
Girard, Marc (Hôpital Notre Dame, CHUM and Universite de Montreal(Canadà))
Eichau Madueño, Sara (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Grammond, Pierre (Hotel-Dieu de Levis (Canadà))
Horakova, Dana (General University Hospital. Charles University in Prague (República Txeca))
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Roos, Izanne (The Royal Melbourne Hospital (Victòria, Austràlia))
Buzzard, Katherine (Box Hill Hospital (Victòria, Austràlia))
Lechner-Scott, Jeanette (University of Newcastle (Austràlia))
Sánchez Menoyo, José Luis (Hospital Universitario Galdakao (Biscaia, País Basc))
Alroughani, Raed (Amiri Hospital (Kuwait))
Prevost, Julie (Centre Integre de Sante et de Services Sociaux des Laurentides (Quebec, Canadà))
Kuhle, Jens (University Hospital Basel (Basilea, Suïssa))
Gray, Orla (South Eastern HSC Trust (Belfast, Irlanda))
Mathey, Guillaume (Université de Lorraine (Nancy, França))
Michel, Laure (Centre Hospitalier Universitaire de Rennes (França))
Ciron, Jonathan (Centre Hospitalier Universitaire de Toulouse (França))
De Sèze, , Jérôme (University of Strasbourg (França))
Maillart, Elisabeth (Hôpital Pitié-Salpêtière (París, França))
Ruet, Aurelie (Université de Bordeaux (França))
Labauge, Pierre (University of Montpellier (MUSE)(França))
Zephir, Helene (Université de Lille (França))
Kwiatkowski, Arnaud (Hôpital Saint Vincent de Paul (Lille, França))
van der Walt, Anneke (The Alfred Hospital (Melbourne, Austràlia))
Kalincik, Tomas (The Royal Melbourne Hospital (Victòria, Austràlia))
Butzkueven, Helmut (Monash University)
Italian MS Register. Observatoire Français de la Sclérose en Plaques (OFSEP). MSBase Study Group. Swedish MS Registry. Big MS Data Network
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Background Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our aim was to investigate the potential effect of DMT on disability worsening among patients with PPMS stratified by different disability trajectories. Methods Within the framework of the Big MS Data network, we merged data from the Observatoire Français de la Sclérose en Plaques, the Swedish and Italian MS registries, and MSBase. We identified patients with PPMS that started DMT or were never treated during the observed period. Subpopulations with comparable baseline characteristics were selected by propensity score matching. Disability outcomes were analysed in time-to-recurrent event analyses, which were repeated in subclasses with different disability trajectories determined by latent class mixed models. Results Of the 3243 included patients, we matched 739 treated and 1330 untreated patients with a median follow-up of 3 years after pairwise censoring. No difference in the risk of confirmed disability worsening (CDW) was observed between the groups in the fully matched dataset (HR 1. 11, 95% CI 0. 97 to 1. 23, p=0. 127). However, we found a lower risk for CDW among the class of treated patients with an aggressive disability trajectory (n=360, HR 0. 68, 95% CI 0. 50 to 0. 92, p=0. 014). Conclusions In line with previous studies, our data suggest that DMT does not ameliorate disability worsening in PPMS, in general. However, we observed a beneficial effect of DMT on disability worsening in patients with aggressive predicted disability trajectories.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Multiple sclerosis
Publicat a:	Journal of Neurology, Neurosurgery, and Psychiatry, Volume 96, Issue 6 (2024) , p. 606-615, ISSN 1468-330X

DOI: 10.1136/jnnp-2024-334700
PMID: 39643429

10 p, 2.0 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats